BioSpace News Archive

Alnylam Pharmaceuticals, Inc. announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021.

Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), today announced members of the Company’s management team will be presenting at the following upcoming medical conferences and invites investors and the research community to attend virtually via webcast

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended September 30, 2021, on Thursday, November 4, 2021, at 4:30 p.m. (ET).

PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, announced that it has appointed Noel Donnelly as Chief Financial Officer.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive acute and long-term interim results from the first 500 pulmonary embolism (“PE”) patients enrolled in the FlowTriever Outcomes Registry (“FLASH”).

Global Blood Therapeutics, Inc. announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after U.S. financial markets close.

Triumvira Immunologics today announced that it has appointed Deyaa Adib, M.D., to serve as the company’s Chief Medical Officer, effective immediately.

Inscopix, Inc. today announced it appointed David Gray, Ph.D., as Chief Scientific Officer (CSO)